Biomarin Pharmaceutical

Patent cliffs & loss of exclusivity

BioMarin Pharmaceutical, Inc is engaged in the development and commercialization of innovative pharmaceuticals for the treatment of serious diseases and diseases

Company

AngelList URLhttps://angel.co/biomarin-pharmaceutical
Legal NameBioMarin Pharmaceutical Inc.
Company Operating StatusActive
Crunchbase URLhttps://www.crunchbase.com/organization/biomarin-pharmaceutical
Facebook URLhttps://www.facebook.com/pages/BioLineRx-Ltd/239324682805429
Fax Number+1 (888) 863-3361 Patient and Physician Support
Full AddressBioMarin Pharmaceutical Inc. 770 Lindaro Street San Rafael, CA 94901, USA
Instagram URLhttps://www.instagram.com/biomarinofficial/

5 upcoming patent cliffs

DrugIngredientTypeCliff
  1. KUVANSAPROPTERIN DIHYDROCHLORIDESmall mol.May 2026
  2. KUVANSAPROPTERIN DIHYDROCHLORIDESmall mol.May 2033
  3. KUVANSAPROPTERIN DIHYDROCHLORIDESmall mol.May 2033
  4. VOXZOGOVOSORITIDESmall mol.Jul 2042
  5. VOXZOGOVOSORITIDESmall mol.Jul 2042
  6. VOXZOGOVOSORITIDESmall mol.Jul 2042
  7. AldurazymelaronidaseBiologic—
  8. NaglazymegalsulfaseBiologic—
  9. Vimizimelosulfase alfaBiologic—
  10. Brineuracerliponase alfaBiologic—
  11. Palynziqpegvaliase-pqpzBiologic—
  12. Palynziqpegvaliase-pqpzBiologic—
  13. Palynziqpegvaliase-pqpzBiologic—

Loss-of-exclusivity dates are derived from the FDA Orange & Purple Books; company detail is from the CliffBio graph. Estimates are projections, not legal advice.